Horizontal gene transfer

Edison issues update on HgCapital Trust (HGT): Strong earnings growth and realisations in FY23

Retrieved on: 
Wednesday, April 10, 2024
Growth, NAV, Horizontal gene transfer, Environment, Hg

HgCapital Trust (HgT) posted an 11.1% NAV total return in FY23 (based on final audited numbers), which allowed it to sustain strong five- and 10-year returns of 20.4% and 18.4% pa, respectively.

Key Points: 
  • HgCapital Trust (HgT) posted an 11.1% NAV total return in FY23 (based on final audited numbers), which allowed it to sustain strong five- and 10-year returns of 20.4% and 18.4% pa, respectively.
  • This has been mostly driven by robust earnings momentum across its portfolio.
  • HgT defied the tough private equity exit environment, generating £345.9m of total realisation proceeds excluding carried interest in FY23.
  • Growth was further assisted by high ‘buy-and-build’ activity, which benefited earnings growth and supported returns through a considerable multiples arbitrage.

Edison issues flash on HgT (HGT): Preliminary FY23 NAV total return of 10.7%

Retrieved on: 
Tuesday, February 6, 2024
Investment, Howden, Growth, JTL, Horizontal gene transfer, NAV, P&I

HgT’s preliminary unaudited FY23 trading update reported a 10.7% net asset value total return (NAV TR) in FY23 (of which c 1% in Q423).

Key Points: 
  • HgT’s preliminary unaudited FY23 trading update reported a 10.7% net asset value total return (NAV TR) in FY23 (of which c 1% in Q423).
  • HgT therefore sustained its multi-year track record of delivering c 20–30% pa revenue and EBITDA growth.
  • The discount narrowing from 23% to 13% during FY23 (now c 14%) translated into a share price TR of 26.2%.
  • HgT was cautious in terms of new and follow-on platform investments in FY23, with total investments of £71m, including GTreasury, Nomadia, JTL, P&I and Howden.

Asia Pacific Cancer Gene Therapy Market Report 2022: Increase in Financing for R&D in Cancer Gene Therapy Activities, as Well as An Increase in the Occurrence of Cancer Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, July 29, 2022
Pharmaceutical, Genetics, Health, Oncology, Transfer, Immunotherapy, Horizontal gene transfer, Genome, Industry, Government, Risk, Conditional sentence, Cancer, Gene, Country, Biotechnology, List of Dove Medical Press academic journals, Growth, Prevalence, Pharmaceutical industry, Vaccine

An increase in financing for R&D in cancer gene therapy activities, as well as an increase in the occurrence of cancer, are two significant reasons driving the market's expansion.

Key Points: 
  • An increase in financing for R&D in cancer gene therapy activities, as well as an increase in the occurrence of cancer, are two significant reasons driving the market's expansion.
  • Furthermore, favorable government laws for therapy are expected to promote numerous prospects that is expected to boost Cancer Gene Therapy Market over the forecast period.
  • However, the high cost of gene therapy, as well as undesired immune reactions, are likely to restrain the growth of the cancer gene therapy market.
  • In addition, the advantages of cancer gene therapy over conventional cancer medicines, as well as an increase in government backing and biotechnology financing that stimulates cancer gene therapy R&D, all contribute to the growth of the market.

The Worldwide Cancer Gene Therapy Industry is Expected to Reach $5 Billion by 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 16, 2022
Genetics, Health, Oncology, Transfer, CAGR, Prostate, Skin, Cancer, Industry, Horizontal gene transfer, COVID-19, Kidney, Attention, Gene, Liver, Brain, Health, Virus, Research, List of Dove Medical Press academic journals, Cell proliferation, DNA, Marketing, Lymphatic system, Immune system, Investment, Lung, RNA interference, Radiation, Immunotherapy, Death, Patient, Pancreas, Cell, Dove Medical Press, Breast, Neoplasm, Vaccine

The Global Cancer Gene Therapy Market size is expected to reach $5 billion by 2028, rising at a market growth of 21.2% CAGR during the forecast period.

Key Points: 
  • The Global Cancer Gene Therapy Market size is expected to reach $5 billion by 2028, rising at a market growth of 21.2% CAGR during the forecast period.
  • The pipeline for cancer gene therapy is quite strong, and various industry participants have recently concentrated their efforts on developing a number of successful cancer gene therapies and vectors.
  • Pre-marketing approval is required for the marketing of cancer gene therapy, and it is a lengthy process that is closely reviewed.
  • Cancer gene therapy is a strategy for treating cancer that involves inserting therapeutic DNA into the patient's gene.

Muscular Dystrophy Association Gathers Global Leaders at Annual Conference, the Largest Convening in the Field of Neuromuscular Disease Research & Care in the World

Retrieved on: 
Wednesday, February 9, 2022
Molecule, Transfer, CRISPR, Industry, Duchenne muscular dystrophy, Muscular Dystrophy Association, Clinical trial, Multimedia, Gaylord Opryland Resort & Convention Center, Episcopal conference, Genetic heterogeneity, ALS, Science, Conference, Doctor of Philosophy, Convention center, Horizontal gene transfer, Session, Invention, Federation, 2021 Essex County Council election, Knowledge, Gene editing, Spinal muscular atrophy, Translation, CEO, Peripheral neuropathy, MDA, Duchenne, Chairperson, Environment, Neuromuscular disease, Telehealth, Drug development, CMT, SMA, Muscular dystrophy, IRIS, View, Degenerative disease, Amyotrophic lateral sclerosis, Charcot–Marie–Tooth disease, MPH, National Sexual Violence Resource Center, COVID-19, Pharmaceutical industry, Medical imaging, Industrial design, DMD, Gene, Research, MD

Day four of the conference will be devoted to oral presentations from selected abstracts submitted by scientific and clinical researchers.

Key Points: 
  • Day four of the conference will be devoted to oral presentations from selected abstracts submitted by scientific and clinical researchers.
  • "MDA's annual conference is the largest and most important convening on advances in understanding and treating neuromuscular diseases in the world.
  • "Our conference is the only one in the neuromuscular space that really combines everything from basic research to clinical care, treatment, and management."
  • For 70 years, the Muscular Dystrophy Association (MDA) has been committed to transforming the lives of people living with muscular dystrophy, ALS, and related neuromuscular diseases.